Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04634817 in Type 2 Diabetes with Overt Nephropathy
NCT01712061Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2012
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in diabetic nephropathy (DN) comparing PF-04634817 with Placebo (2 arms). Primary endpoint: Urinary Albumin to Creatinine Ratio at 12 weeks. Started Dec 2012; status: completed.
02
Drugs
PF-04634817
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT01712061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01712061.